Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheim-Chester disease patients following BRAF inhibitor monotherapy

Keyphrases

• Monotherapy 100%
• Erdheim-Chester Disease 100%
• BRAF Inhibitor (BRAFi) 100%
• BRAF mutant 100%
• Vemurafenib 66%
• Disease Progression 33%
• Magnetic Resonance Imaging 33%
• Therapeutic Strategies 33%
• CNS Disorders 33%
• Cobimetinib 33%
• Long-term Treatment 16%
• Metabolic 16%
• Remission 16%
• Combination Therapy 16%
• Response to Therapy 16%
• Treatment Regimen 16%
• Clinical Improvement 16%
• Constitutive Activation 16%
• Suboptimal Response 16%
• Mitogen-activated Protein Kinase 16%
• Lack of Response 16%
• Biological Treatment 16%
• Long-term Management 16%
• Extracranial 16%
• Mutant BRAF 16%
• Myeloid Neoplasms 16%
• Dual Therapy 16%
• Neurological Improvement 16%
• V600E 16%
• 18F-fludeoxyglucose Positron Emission Tomography/computed Tomography 16%
• RAF Kinase 16%
• Dual Inhibition 16%

Medicine and Dentistry

• Monotherapy 100%
• Erdheim-Chester Disease 100%
• Vemurafenib 66%
• Disease 33%
• Central Nervous System Disease 33%
• Disease Exacerbation 33%
• Magnetic Resonance Imaging 33%
• Cobimetinib 33%
• Signal Transduction 16%
• Neoplasm 16%
• Combination Therapy 16%
• Positron Emission Tomography-Computed Tomography 16%
• MAPK Signaling 16%
• Fludeoxyglucose (18F) 16%
• B Raf Kinase 16%
• Polyethylene Terephthalate 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Monotherapy 100%
• Erdheim Chester Disease 100%
• Vemurafenib 66%
• Disease 33%
• Disease Exacerbation 33%
• Central Nervous System Disease 33%
• Cobimetinib 33%
• Neoplasm 16%
• Combination Therapy 16%
• Remission 16%
• Fluorine 18 16%
• B Raf Kinase 16%
• Polyethylene Terephthalate 16%